Use the search bar to search by drug, manufacturer, or indication. You can also filter your search results by drug, manufacturer, or negotiation status.
To learn more about a specific file, click on a drug name. It will open its product card, which includes information about the manufacturer, indication (the approved use of a drug by Health Canada), and negotiation milestones.
There are 6 negotiation statuses, which reflect where the drug file is in the pCPA process:
Under consideration for negotiation
We’re considering the evidence and gathering other information to inform the negotiation approach, including eligibility for expedited negotiation pathways.
Active negotiation
Negotiation activities are underway for the drug, with our negotiation team and the manufacturer meeting regularly.
Concluded with an LOI
Negotiations ended successfully with mutually agreed-upon terms, and these terms are outlined in a letter of intent (LOI).
Concluded without agreement
Negotiating parties couldn’t agree on terms. Negotiations have ended without a pricing agreement for the drug.
Negotiation not pursued
It has been decided, in partnership with our member drug plans, not to engage in a negotiation. Typically, this is because the drug’s health technology (HTA) assessment reimbursement recommendations were negative, or “do not reimburse.” Other reasons, like the manufacturer declining to negotiate or a lack of supply of the drug in Canada, may be reflected in an accompanying status note.
Negotiation on hold
We began negotiation activities for the drug, but they’ve since been paused. An accompanying status note indicates whether the pause was requested by the manufacturer or the pCPA.
Learn more
To learn more about our negotiation processes, or where the pCPA fits into the Canadian drug reimbursement system, consult these pages:
Bijuva (estradiol and progesterone)
Status:
Concluded with an LOI
Manufacturer:
Knight Therapeutics Inc.
Indication:
Vasomotor symptoms associated with menopause
Last updated:
May 30, 2023
Enhertu (trastuzumab deruxtecan)
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adult patients who have received a prior treatment with an anti-HER2-based regimen in the metastatic setting or developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy
Last updated:
May 29, 2023
Status:
Concluded with an LOI
Manufacturer:
Bristol Myers Squibb Canada Inc.
Indication:
Resectable Non-small cell lung cancer (tumours ?4cm or node positive), neoadjuvant treatment of adult patients, when used in combination with platinum-doublet chemotherapy
Last updated:
May 25, 2023
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients
Last updated:
May 19, 2023
Status:
Concluded with an LOI
Manufacturer:
Forus Therapeutics Inc.
Indication:
Multiple myeloma (MM) in adults with who have received at least one prior therapy (In combination with bortezomib (V) and dexamethasone (d))
Last updated:
May 15, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. (in combination with Lenvatinib (Lenvima))
Last updated:
May 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), in adult patients who have disease progression following prior platinum-based systemic therapy, and are not candidates for curative surgery or radiation. (in combination with Lenvatinib (Lenvima))
Last updated:
May 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Advanced or metastatic renal cell carcinoma (RCC) in adult patients with no prior systemic therapy for metastatic RCC (in combination with Lenvima)
Last updated:
May 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Advanced or metastatic renal cell carcinoma (RCC) in adult patients with no prior systemic therapy for metastatic RCC (in combination with Lenvima)
Last updated:
May 12, 2023
Status:
Concluded with an LOI
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with imatinib, sunitinib, and regorafenib
Last updated:
May 12, 2023